Annual CFF
$8.40 M
+$8.61 M+4204.00%
December 31, 2023
Summary
- As of February 7, 2025, IKT annual cash flow from financing activities is $8.40 million, with the most recent change of +$8.61 million (+4204.00%) on December 31, 2023.
- During the last 3 years, IKT annual CFF has fallen by -$6.66 million (-44.21%).
- IKT annual CFF is now -79.55% below its all-time high of $41.09 million, reached on December 31, 2021.
Performance
IKT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$182.00 K
-$3.06 M-94.39%
September 30, 2024
Summary
- As of February 7, 2025, IKT quarterly cash flow from financing activities is $182.00 thousand, with the most recent change of -$3.06 million (-94.39%) on September 30, 2024.
- Over the past year, IKT quarterly CFF has dropped by -$3.06 million (-94.39%).
- IKT quarterly CFF is now -99.56% below its all-time high of $41.47 million, reached on June 30, 2021.
Performance
IKT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$3.66 M
+$181.90 K+5.24%
September 30, 2024
Summary
- As of February 7, 2025, IKT TTM cash flow from financing activities is $3.66 million, with the most recent change of +$181.90 thousand (+5.24%) on September 30, 2024.
- Over the past year, IKT TTM CFF has increased by +$181.90 thousand (+5.24%).
- IKT TTM CFF is now -93.47% below its all-time high of $55.98 million, reached on September 30, 2021.
Performance
IKT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
IKT Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4204.0% | -94.4% | +5.2% |
| 3 y3 years | -44.2% | -97.9% | -57.4% |
| 5 y5 years | +2013.7% | -97.9% | -57.4% |
IKT Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -79.5% | +4204.0% | -97.9% | +188.9% | -91.2% | +1884.8% |
| 5 y | 5-year | -79.5% | +4204.0% | -99.6% | +144.4% | -93.5% | +1884.8% |
| alltime | all time | -79.5% | +2013.7% | -99.6% | +144.4% | -93.5% | +1884.8% |
Inhibikase Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $182.00 K(-94.4%) | $3.66 M(+5.2%) |
| Jun 2024 | - | $3.24 M(+784.0%) | $3.47 M(+1699.6%) |
| Mar 2024 | - | $367.00 K(-365.7%) | $193.00 K(-97.7%) |
| Dec 2023 | $8.40 M(-4204.0%) | -$138.10 K(<-9900.0%) | $8.40 M(-1.6%) |
| Sep 2023 | - | $100.00(-100.3%) | $8.54 M(+0.0%) |
| Jun 2023 | - | -$36.00 K(-100.4%) | $8.54 M(-0.4%) |
| Mar 2023 | - | $8.58 M(>+9900.0%) | $8.58 M(-4289.0%) |
| Dec 2022 | -$204.80 K(-100.5%) | $0.00(0.0%) | -$204.80 K(0.0%) |
| Sep 2022 | - | $0.00(0.0%) | -$204.80 K(+17.1%) |
| Jun 2022 | - | $0.00(-100.0%) | -$174.90 K(-100.4%) |
| Mar 2022 | - | -$204.80 K(<-9900.0%) | $41.30 M(+0.5%) |
| Dec 2021 | $41.09 M | $0.00(-100.0%) | $41.09 M(-26.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | $29.90 K(-99.9%) | $55.98 M(+0.2%) |
| Jun 2021 | - | $41.47 M(<-9900.0%) | $55.88 M(+287.9%) |
| Mar 2021 | - | -$409.70 K(-102.8%) | $14.40 M(-4.4%) |
| Dec 2020 | $15.06 M(<-9900.0%) | $14.88 M(<-9900.0%) | $15.06 M(+8241.4%) |
| Sep 2020 | - | -$67.10 K(+2695.8%) | $180.60 K(-27.1%) |
| Jun 2020 | - | -$2400.00(-101.0%) | $247.70 K(-1.0%) |
| Mar 2020 | - | $250.10 K(>+9900.0%) | $250.10 K(-1196.9%) |
| Dec 2019 | -$22.80 K(-94.8%) | $0.00(0.0%) | -$22.80 K(0.0%) |
| Sep 2019 | - | $0.00(0.0%) | -$22.80 K(0.0%) |
| Jun 2019 | - | $0.00(-100.0%) | -$22.80 K(0.0%) |
| Mar 2019 | - | -$22.80 K | -$22.80 K |
| Dec 2018 | -$439.20 K | - | - |
FAQ
- What is Inhibikase Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual CFF year-on-year change?
- What is Inhibikase Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly CFF year-on-year change?
- What is Inhibikase Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics TTM CFF year-on-year change?
What is Inhibikase Therapeutics annual cash flow from financing activities?
The current annual CFF of IKT is $8.40 M
What is the all time high annual CFF for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual cash flow from financing activities is $41.09 M
What is Inhibikase Therapeutics annual CFF year-on-year change?
Over the past year, IKT annual cash flow from financing activities has changed by +$8.61 M (+4204.00%)
What is Inhibikase Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of IKT is $182.00 K
What is the all time high quarterly CFF for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly cash flow from financing activities is $41.47 M
What is Inhibikase Therapeutics quarterly CFF year-on-year change?
Over the past year, IKT quarterly cash flow from financing activities has changed by -$3.06 M (-94.39%)
What is Inhibikase Therapeutics TTM cash flow from financing activities?
The current TTM CFF of IKT is $3.66 M
What is the all time high TTM CFF for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high TTM cash flow from financing activities is $55.98 M
What is Inhibikase Therapeutics TTM CFF year-on-year change?
Over the past year, IKT TTM cash flow from financing activities has changed by +$181.90 K (+5.24%)